hg-9-91-01 and 2-4-diaminopyrimidine

Novel methods for the treatment of inflammatory and autoimmune diseases comprising the administration of salt-inducible kinase inhibitors are claimed. One novel inhibitor (HG-9-91-01) and the use of 2,4-diaminopyrimidine and 2,6-diaminopyrimidine derivatives are claimed. The use of such inhibitors upregulates the level of the anti-inflammatory cytokine IL-10 in macrophages.

Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Drug Design; Enzyme Inhibitors; Humans; Inflammation; Interleukin-10; Macrophages; Patents as Topic; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyrimidines